Ovarian Cancer: BRCA Genetics Reveals Targets for New Therapies

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Genetic Syndromes & Gene Therapy

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4172/2157-7412.1000209
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA 1 and BRCA 2

  2015cited by this paper
• Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.

  2013cited by this paper
• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

  2013cited by this paper
• Mechanisms of resistance to therapies targeting BRCA-mutant cancers

  2013cited by this paper
• Case Report: Complete Clinical Response of a Young Patient with a BRCA 2 Positive Metastatic Breast Cancer

  2013cited by this paper
• From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade.

  2012cited by this paper
• Germline BRCA mutation does not prevent response to taxane‐based therapy for the treatment of castration‐resistant prostate cancer

  2012cited by this paper
• Hereditary ovarian cancer: beyond the usual suspects.

  2012cited by this paper
• The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers

  2012cited by this paper
• BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence

  2012cited by this paper
• Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

  2012cited by this paper
• Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management

  2012cited by this paper
• BRCAness: finding the Achilles heel in ovarian cancer.

  2012cited by this paper
• Rethinking ovarian cancer: recommendations for improving outcomes

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer.

  2011influential reference
• The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

  2011cited by this paper
• Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

  2011cited by this paper
• BRCA1 and BRCA2: different roles in a common pathway of genome protection

  2011cited by this paper
• Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

  2011cited by this paper
• Poly(ADP‐Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

  2011cited by this paper
• Unraveling the mechanism of BRCA2 in homologous recombination

  2011cited by this paper
• Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.

  2011cited by this paper
• PARP inhibition: PARP1 and beyond

  2010cited by this paper
• Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

  2010cited by this paper
• Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC).

  2010cited by this paper
• Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

  2010influential reference
• Cancer Statistics, 2010

  2010cited by this paper
• Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

  2010cited by this paper
• Cancer Statistics, 2009

  2010cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Family History of Cancer Rather Than p53 Status Predicts Efficacy of Pegylated Liposomal Doxorubicin and Oxaliplatin in Relapsed Ovarian Cancer

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• PALB2 is an integral component of the BRCA complex required for homologous recombination repair

  2009cited by this paper
• Resistance to therapy caused by intragenic deletion in BRCA2

  2008cited by this paper
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

  2008cited by this paper
• New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

  2008cited by this paper
• A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.

  2008influential reference
• Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

  2008cited by this paper
• "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

  2008cited by this paper
• A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

  2007cited by this paper
• PALB2-new breast-cancer susceptibility gene.

  2007cited by this paper
• The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly.

  2006cited by this paper
• Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.

  2006cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

  2005cited by this paper
• Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

  2005influential reference
• DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance

  2004cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Genetic Steps of Mammalian Homologous Repair with Distinct Mutagenic Consequences

  2004cited by this paper
• Improved survival in women with BRCA‐associated ovarian carcinoma

  2003cited by this paper
• Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors

  2003cited by this paper
• EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.

  2003cited by this paper
• Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

  2003cited by this paper
• Frequency of BRCA1 dysfunction in ovarian cancer.

  2002cited by this paper
• Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

  2002cited by this paper
• Effect of BRCA mutations on the length of survival in epithelial ovarian tumors.

  2002cited by this paper
• Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair

  2001cited by this paper
• Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.

  2001cited by this paper
• Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

  2001cited by this paper
• Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer

  2001cited by this paper
• Antitumor compounds from tunicates

  2000cited by this paper
• Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

  2000cited by this paper
• BRCA1 inhibition of estrogen receptor signaling in transfected cells.

  1999cited by this paper
• Brca1 controls homology-directed DNA repair.

  1999cited by this paper
• Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene

  1997cited by this paper
• Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer.

  1996cited by this paper
• Identification of the breast cancer susceptibility gene BRCA2

  1995cited by this paper
• Somatic mutations in the BRCA1 gene in sporadic ovarian tumours

  1995cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• Molecular genetics for the clinician

  1993cited by this paper
• Cancer statistics

  1989cited by this paper
• Familial association of carcinoma of the breast and ovary.

  1974cited by this paper

• Circulating and tissue microRNAs as biomarkers for ovarian cancer prognosis.

  2019cites this paper
• Current state of biomarkers in ovarian cancer prognosis.

  2015cites this paper